TISIDB

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Membrane Peripheral membrane protein Cytoplasm, cytoskeleton Cytoplasm, myofibril, sarcomere, Z line Note=A small amount localizes at membranes. In striated muscle cells, it predominantly localizes in myofibrillar Z lines, while a minor fraction localizes with subsarcolemme. Targeting to developing and mature Z lines is mediated by the intradomain insert.
Domain	PF00307 Calponin homology (CH) domain PF00630 Filamin/ABP280 repeat
Function	Muscle-specific filamin, which plays a central role in muscle cells, probably by functioning as a large actin-cross-linking protein. May be involved in reorganizing the actin cytoskeleton in response to signaling events, and may also display structural functions at the Z lines in muscle cells. Critical for normal myogenesis and for maintaining the structural integrity of the muscle fibers.

> Gene Ontology [ TOP ]
Biological Process	GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0042692 muscle cell differentiation GO:0048747 muscle fiber development GO:0051146 striated muscle cell differentiation GO:0055001 muscle cell development GO:0055002 striated muscle cell development
Molecular Function	GO:0003779 actin binding GO:0030506 ankyrin binding GO:0051015 actin filament binding
Cellular Component	GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0016528 sarcoplasm GO:0030016 myofibril GO:0030017 sarcomere GO:0030018 Z disc GO:0030055 cell-substrate junction GO:0031674 I band GO:0042383 sarcolemma GO:0043034 costamere GO:0043292 contractile fiber GO:0044449 contractile fiber part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04510 Focal adhesion
Reactome	R-HSA-446728: Cell junction organization R-HSA-1500931: Cell-Cell communication R-HSA-446353: Cell-extracellular matrix interactions

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FLNC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FLNC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FLNC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.705	0.238
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.125	0.289
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.387	0.642
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.12	0.28
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.068	0.735
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.184	0.768
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.358	0.516
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.301	0.782
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.523	0.632
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	2.649	0.054
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.715	0.164
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.519	0.0392

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FLNC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	35.7	17.6	18.1	0.412
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	50	33.3	16.7	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	14.3	-14.3	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	5.5	16.7	0.0222
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	5.1	17.1	0.0245
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	23.5	0.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	27.3	3.5	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	33.3	12.5	20.8	0.312
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	22.2	-2.2	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	0	50	0.109
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	15.8	3.7	12.1	0.224
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	22.7	7.7	15	0.377
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FLNC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FLNC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FLNC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FLNC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FLNC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FLNC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FLNC
Name	filamin C, gamma
Aliases	ABPL; FLN2; filamin C, gamma (actin binding protein 280); ABP280A; ABPA; MFM5; MPD4; ABP-280-like protein; A ......
Chromosomal Location	7q32-q35
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FLNC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FLNC